Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 9/20 | 0.66 |
| ▸ | MMP1 | P03956 | 3/20 | 0.66 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.66 |
| ▸ | MMP3 | P08254 | 2/20 | 0.56 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504731 | 0.87 | ADAM17 (0.58) | ADAM17MMP1ADAM10MMP3MMP2 | |
| SCHEMBL2682234 | 0.85 | ADAM17 (0.67) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL1503684 | 0.84 | ADAM17 (0.87) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL1503682 | 0.84 | ADAM17 (0.87) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL1503643 | 0.80 | ADAM17 (0.83) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL12076785 | 0.80 | ADAM17 (1.00) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL1503524 | 0.80 | ADAM17 (1.00) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL1503609 | 0.80 | ADAM17 (1.00) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL1503588 | 0.80 | ADAM17 (1.00) | ADAM17MMP1ADAM10MMP3ADAM33 | |
| SCHEMBL12076903 | 0.80 | ADAM17 (1.00) | ADAM17MMP1ADAM10MMP3ADAM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011033010-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |